Phase 2 Trial | Nivolumab shows promise as adjuvant therapy in completely resected Merkel cell carcinoma

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Adjuvant Nivolumab vs Observation for Patients With Completely Resected Merkel Cell Carcinoma – The ASCO Post